Abstract

We attempt to discuss the improvement of clinical efficacy of imipenem in intensive care unit patients with severe pneumonia and its effect on serum C-reactive protein, procalcitonin and interleukin 6. We selected 70 patients with severe pneumonia who accepted therapy in intensive care unit of our hospital from February 2019 to June 2021 as participants. Randomly divided them into two groups, one was an experimental group and the other was control group (n=35). Treated control group with routine treatment such as antiinfection, phlegm and mechanical ventilation and other basic therapies, after receiving the same treatment as control group, treated experimental group with another imipenem, then compared both groups on acute physiology and chronic health evaluation II score, clinical effective rate, arterial blood gas and serum procalcitonin, C-reactive protein, interleukin 6 before and after therapy. After 3 d and 7 d treatment of groups, acute physiology and chronic health evaluation II score and partial pressure of carbon dioxide of experimental group had a greater downward trend than control group, but partial pressure of oxygen had a faster upward trend than control group. There was a remarkable difference, so it possessed statistical significance (p<0.05). Serum procalcitonin, C-reactive protein and interleukin 6 of experimental group had a greater downward trend than control group, with remarkable divergences (p<0.05). Total clinical effective rate of experimental group (91.4 %) was remarkably higher than control group (71.4 %) and it possessed significant difference (p<0.05). Imipenem can significantly improve the clinical effective rate of severe pneumonia, reduce the concentration of serum procalcitonin, C-reactive protein and interleukin 6, and provide clinical guidance value for the effective treatment of severe pneumonia.